An Overview on Tissue Engineered Models for Cancer Study
DOI:
https://doi.org/10.22034/JATE.2018.18Keywords:
Tissue engineering, Cancer, 3D modelsAbstract
There is increasing recognition that three-dimensional (3D) tissue culture technologies have many uses within the biomedical sciences beyond the scope of regenerative medicine. Three-dimensional models show clearer results than other two-dimensional models for testing anticancer drugs. Advances in tissue engineering have traditionally led to the design of scaffold- or matrix-based culture systems that can better reflect the biological, physical and biochemical environment of the natural extracellular matrix. Since developing new therapies for cancer is closely related to the understanding of the basic principles that are applied in tissue engineering models. In this study, we introduce some tissue engineered models of cancer
References
1.Naderi H, Matin MM, Bahrami AR. Review paper: critical issues in tissue engineering: biomaterials, cell sources, angiogenesis, and drug delivery systems. Journal of biomaterials applications. 2011;26(4):383-417.
2.Yeong W-Y, Chua C-K, Leong K-F, Chandrasekaran M. Rapid prototyping in tissue engineering: challenges and potential. Trends in biotechnology. 2004;22(12):643-52.
3.Sachlos E, Czernuszka J. Making tissue engineering scaffolds work. Review: the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. Eur Cell Mater. 2003;5(29):39-40.
4.Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Developmental biology. 2007;302(1):1-12.
5.Szekeres T, Novotny L. New targets and drugs in cancer chemotherapy. Medical Principles and Practice. 2002;11(3):117-25.
6.Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer. 2006;6(10):813-23.
7.Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clinical Cancer Research. 2003;9(11):4227-39.
8.Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Molecular cancer. 2006;5(1):55.
9.Van Staveren W, Solís DW, Hebrant A, Detours V, Dumont JE, Maenhaut C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2009;1795(2):92-103.
10.Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nature Reviews Cancer. 2004;4(11):839-49.
11.Kung AL. Practices and pitfalls of mouse cancer models in drug discovery. Advances in cancer research. 2006;96:191-212.
12.Teicher BA. Tumor models for efficacy determination. Molecular cancer therapeutics. 2006;5(10):2435-43.
13.Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer and Metastasis Reviews. 1998;17(3):279-84.
14.Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature reviews Drug discovery. 2006;5(9):741-54.
15.Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. The American journal of pathology. 2007;170(3):793-804.
16.Burdett E, Kasper FK, Mikos AG, Ludwig JA. Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Engineering Part B: Reviews. 2010;16(3):351-9.
17.Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene. 2002;21(2):307.
18.Sutherland RM, Inch WR, McCredie JA, Kruuv J. A multi-component radiation survival curve using an in vitro tumour model. International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine. 1970;18(5):491-5.
19.Yuhas JM, Li AP, Martinez AO, Ladman AJ. A simplified method for production and growth of multicellular tumor spheroids. Cancer research. 1977;37(10):3639-43.
20.Lin RZ, Chang HY. Recent advances in three‐dimensional multicellular spheroid culture for biomedical research. Biotechnology journal. 2008;3(9‐10):1172-84.
21.Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nature protocols. 2009;4(3):309-24.
22.Timmins NE, Nielsen LK. Generation of multicellular tumor spheroids by the hanging-drop method. Tissue Engineering. 2007:141-51.
23.Wu LY, Di Carlo D, Lee LP. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomedical microdevices. 2008;10(2):197-202.
24.Kang H-G, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer research. 2007;67(7):3094-105.
25.Ng KW, Leong DT, Hutmacher DW. The challenge to measure cell proliferation in two and three dimensions. Tissue Engineering. 2005;11(1-2):182-91.
26.Hubbell JA. Biomaterials in tissue engineering. Nature Biotechnology. 1995;13(6):565-76.
27.Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proceedings of the National Academy of Sciences. 1986;83(8):2694-8.
28.Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. Critical reviews in oncology/hematology. 2000;36(2):61-74.
29.Xu F, Burg KJ. Three-dimensional polymeric systems for cancer cell studies. Cytotechnology. 2007;54(3):135-43.
30.O'Keane J, Kupchik H, Schroy P, Andry C, Collins E, O'Brien M. A three-dimensional system for long-term culture of human colorectal adenomas. The American journal of pathology. 1990;137(6):1539.
31.Kleinman HK, Martin GR, editors. Matrigel: basement membrane matrix with biological activity. Seminars in cancer biology; 2005: Elsevier.
32.Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis. 1997;18(6):1225-31.
33.Dhiman HK, Ray AR, Panda AK. Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. Biomaterials. 2005;26(9):979-86.
34.Dhiman HK, Ray AR, Panda AK. Characterization and evaluation of chitosan matrix for in vitro growth of MCF-7 breast cancer cell lines. Biomaterials. 2004;25(21):5147-54.
35.Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, et al. 3-D tumor model for in vitro evaluation of anticancer drugs. Molecular pharmaceutics. 2008;5(5):849-62.
36.Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al. Engineering tumors with 3D scaffolds. Nature methods. 2007;4(10):855-60.
37.de Jong GM, Aarts F, Hendriks T, Boerman OC, Bleichrodt RP. Animal models for liver metastases of colorectal cancer: research review of preclinical studies in rodents. Journal of Surgical Research. 2009;154(1):167-76.
38.Meyvantsson I, Beebe DJ. Cell culture models in microfluidic systems. Annu Rev Anal Chem. 2008;1:423-49.
39.Théry M, Racine V, Pépin A, Piel M, Chen Y, Sibarita J-B, et al. The extracellular matrix guides the orientation of the cell division axis. Nature cell biology. 2005;7(10):947-53.
40.Sawano A, Takayama S, Matsuda M, Miyawaki A. Lateral propagation of EGF signaling after local stimulation is dependent on receptor density. Developmental cell. 2002;3(2):245-57.
41.Dittrich PS, Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nature reviews Drug discovery. 2006;5(3):210.
42.Toepke MW, Beebe DJ. PDMS absorption of small molecules and consequences in microfluidic applications. Lab on a Chip. 2006;6(12):1484-6.
43.Zervantonakis IK, Chung S, Sudo R, Zhang M, Charest JL, Kamm RD. Concentration gradients in microfluidic 3D matrix cell culture systems. International Journal of Micro-Nano Scale Transport. 2010;1(1):27-36.
44.Abhyankar VV, Toepke MW, Cortesio CL, Lokuta MA, Huttenlocher A, Beebe DJ. A platform for assessing chemotactic migration within a spatiotemporally defined 3D microenvironment. Lab on a Chip. 2008;8(9):1507-15.
45.Huang CP, Lu J, Seon H, Lee AP, Flanagan LA, Kim H-Y, et al. Engineering microscale cellular niches for three-dimensional multicellular co-cultures. Lab on a Chip. 2009;9(12):1740-8.
46.Sung KE, Beebe DJ. Microfluidic 3D models of cancer. Advanced drug delivery reviews. 2014;79:68-78.
47.DelNero P, Song YH, Fischbach C. Microengineered tumor models: insights & opportunities from a physical sciences-oncology perspective. Biomedical microdevices. 2013;15(4):583-93.
48.Buchanan C, Rylander MN. Microfluidic culture models to study the hydrodynamics of tumor progression and therapeutic response. Biotechnology and bioengineering. 2013;110(8):2063-72.
49.Stroock AD, Fischbach C. Microfluidic culture models of tumor angiogenesis. Tissue Engineering Part A. 2010;16(7):2143-6.
50.McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer cell. 2015;27(1):15-26.
51.Clevers H. The cancer stem cell: premises, promises and challenges. Nature medicine. 2011:313-9.
52.Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Current opinion in genetics & development. 2014;24:68-73.
53.Wills ES, Drenth JP. Building pancreatic organoids to aid drug development. Gut. 2017;66(3):393-4.
54.Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176-87.
55.Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids. Nature medicine. 2015;21(11):1364.
2.Yeong W-Y, Chua C-K, Leong K-F, Chandrasekaran M. Rapid prototyping in tissue engineering: challenges and potential. Trends in biotechnology. 2004;22(12):643-52.
3.Sachlos E, Czernuszka J. Making tissue engineering scaffolds work. Review: the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. Eur Cell Mater. 2003;5(29):39-40.
4.Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Developmental biology. 2007;302(1):1-12.
5.Szekeres T, Novotny L. New targets and drugs in cancer chemotherapy. Medical Principles and Practice. 2002;11(3):117-25.
6.Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer. 2006;6(10):813-23.
7.Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clinical Cancer Research. 2003;9(11):4227-39.
8.Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Molecular cancer. 2006;5(1):55.
9.Van Staveren W, Solís DW, Hebrant A, Detours V, Dumont JE, Maenhaut C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2009;1795(2):92-103.
10.Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nature Reviews Cancer. 2004;4(11):839-49.
11.Kung AL. Practices and pitfalls of mouse cancer models in drug discovery. Advances in cancer research. 2006;96:191-212.
12.Teicher BA. Tumor models for efficacy determination. Molecular cancer therapeutics. 2006;5(10):2435-43.
13.Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer and Metastasis Reviews. 1998;17(3):279-84.
14.Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature reviews Drug discovery. 2006;5(9):741-54.
15.Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. The American journal of pathology. 2007;170(3):793-804.
16.Burdett E, Kasper FK, Mikos AG, Ludwig JA. Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Engineering Part B: Reviews. 2010;16(3):351-9.
17.Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene. 2002;21(2):307.
18.Sutherland RM, Inch WR, McCredie JA, Kruuv J. A multi-component radiation survival curve using an in vitro tumour model. International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine. 1970;18(5):491-5.
19.Yuhas JM, Li AP, Martinez AO, Ladman AJ. A simplified method for production and growth of multicellular tumor spheroids. Cancer research. 1977;37(10):3639-43.
20.Lin RZ, Chang HY. Recent advances in three‐dimensional multicellular spheroid culture for biomedical research. Biotechnology journal. 2008;3(9‐10):1172-84.
21.Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nature protocols. 2009;4(3):309-24.
22.Timmins NE, Nielsen LK. Generation of multicellular tumor spheroids by the hanging-drop method. Tissue Engineering. 2007:141-51.
23.Wu LY, Di Carlo D, Lee LP. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomedical microdevices. 2008;10(2):197-202.
24.Kang H-G, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer research. 2007;67(7):3094-105.
25.Ng KW, Leong DT, Hutmacher DW. The challenge to measure cell proliferation in two and three dimensions. Tissue Engineering. 2005;11(1-2):182-91.
26.Hubbell JA. Biomaterials in tissue engineering. Nature Biotechnology. 1995;13(6):565-76.
27.Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proceedings of the National Academy of Sciences. 1986;83(8):2694-8.
28.Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. Critical reviews in oncology/hematology. 2000;36(2):61-74.
29.Xu F, Burg KJ. Three-dimensional polymeric systems for cancer cell studies. Cytotechnology. 2007;54(3):135-43.
30.O'Keane J, Kupchik H, Schroy P, Andry C, Collins E, O'Brien M. A three-dimensional system for long-term culture of human colorectal adenomas. The American journal of pathology. 1990;137(6):1539.
31.Kleinman HK, Martin GR, editors. Matrigel: basement membrane matrix with biological activity. Seminars in cancer biology; 2005: Elsevier.
32.Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis. 1997;18(6):1225-31.
33.Dhiman HK, Ray AR, Panda AK. Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. Biomaterials. 2005;26(9):979-86.
34.Dhiman HK, Ray AR, Panda AK. Characterization and evaluation of chitosan matrix for in vitro growth of MCF-7 breast cancer cell lines. Biomaterials. 2004;25(21):5147-54.
35.Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, et al. 3-D tumor model for in vitro evaluation of anticancer drugs. Molecular pharmaceutics. 2008;5(5):849-62.
36.Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al. Engineering tumors with 3D scaffolds. Nature methods. 2007;4(10):855-60.
37.de Jong GM, Aarts F, Hendriks T, Boerman OC, Bleichrodt RP. Animal models for liver metastases of colorectal cancer: research review of preclinical studies in rodents. Journal of Surgical Research. 2009;154(1):167-76.
38.Meyvantsson I, Beebe DJ. Cell culture models in microfluidic systems. Annu Rev Anal Chem. 2008;1:423-49.
39.Théry M, Racine V, Pépin A, Piel M, Chen Y, Sibarita J-B, et al. The extracellular matrix guides the orientation of the cell division axis. Nature cell biology. 2005;7(10):947-53.
40.Sawano A, Takayama S, Matsuda M, Miyawaki A. Lateral propagation of EGF signaling after local stimulation is dependent on receptor density. Developmental cell. 2002;3(2):245-57.
41.Dittrich PS, Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nature reviews Drug discovery. 2006;5(3):210.
42.Toepke MW, Beebe DJ. PDMS absorption of small molecules and consequences in microfluidic applications. Lab on a Chip. 2006;6(12):1484-6.
43.Zervantonakis IK, Chung S, Sudo R, Zhang M, Charest JL, Kamm RD. Concentration gradients in microfluidic 3D matrix cell culture systems. International Journal of Micro-Nano Scale Transport. 2010;1(1):27-36.
44.Abhyankar VV, Toepke MW, Cortesio CL, Lokuta MA, Huttenlocher A, Beebe DJ. A platform for assessing chemotactic migration within a spatiotemporally defined 3D microenvironment. Lab on a Chip. 2008;8(9):1507-15.
45.Huang CP, Lu J, Seon H, Lee AP, Flanagan LA, Kim H-Y, et al. Engineering microscale cellular niches for three-dimensional multicellular co-cultures. Lab on a Chip. 2009;9(12):1740-8.
46.Sung KE, Beebe DJ. Microfluidic 3D models of cancer. Advanced drug delivery reviews. 2014;79:68-78.
47.DelNero P, Song YH, Fischbach C. Microengineered tumor models: insights & opportunities from a physical sciences-oncology perspective. Biomedical microdevices. 2013;15(4):583-93.
48.Buchanan C, Rylander MN. Microfluidic culture models to study the hydrodynamics of tumor progression and therapeutic response. Biotechnology and bioengineering. 2013;110(8):2063-72.
49.Stroock AD, Fischbach C. Microfluidic culture models of tumor angiogenesis. Tissue Engineering Part A. 2010;16(7):2143-6.
50.McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer cell. 2015;27(1):15-26.
51.Clevers H. The cancer stem cell: premises, promises and challenges. Nature medicine. 2011:313-9.
52.Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Current opinion in genetics & development. 2014;24:68-73.
53.Wills ES, Drenth JP. Building pancreatic organoids to aid drug development. Gut. 2017;66(3):393-4.
54.Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176-87.
55.Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids. Nature medicine. 2015;21(11):1364.
Downloads
Published
2019-12-10
How to Cite
Rezakhani, L. ., Alizadeh, M. ., & Alizadeh, A. . (2019). An Overview on Tissue Engineered Models for Cancer Study. The Journal of Applied Tissue Engineering, 5(1), 1–11. https://doi.org/10.22034/JATE.2018.18
Issue
Section
Review Articels
